S100A12 acts as a pro-inflammatory agent in vivo, with a close relationship with plaque formation in patients with acute coronary syndrome (ACS), end-stage renal disease, and diabetes. This evidence concerns the gene S100A12 and stage 5 chronic kidney disease.